ATE542897T1 - An der immortalisierung einer menschlichen krebszelle beteiligtes gen und verwendung davon - Google Patents

An der immortalisierung einer menschlichen krebszelle beteiligtes gen und verwendung davon

Info

Publication number
ATE542897T1
ATE542897T1 AT07767074T AT07767074T ATE542897T1 AT E542897 T1 ATE542897 T1 AT E542897T1 AT 07767074 T AT07767074 T AT 07767074T AT 07767074 T AT07767074 T AT 07767074T AT E542897 T1 ATE542897 T1 AT E542897T1
Authority
AT
Austria
Prior art keywords
cancer cell
immortalization
gene
human cancer
gene involved
Prior art date
Application number
AT07767074T
Other languages
English (en)
Inventor
Masahiko Nishiyama
Keiko Hiyama
Keiji Tanimoto
Norio Masuko
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Application granted granted Critical
Publication of ATE542897T1 publication Critical patent/ATE542897T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT07767074T 2006-06-09 2007-06-08 An der immortalisierung einer menschlichen krebszelle beteiligtes gen und verwendung davon ATE542897T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006161350 2006-06-09
PCT/JP2007/061652 WO2007142336A1 (ja) 2006-06-09 2007-06-08 ヒトがん細胞の不死化に関わる遺伝子およびその利用

Publications (1)

Publication Number Publication Date
ATE542897T1 true ATE542897T1 (de) 2012-02-15

Family

ID=38801580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07767074T ATE542897T1 (de) 2006-06-09 2007-06-08 An der immortalisierung einer menschlichen krebszelle beteiligtes gen und verwendung davon

Country Status (10)

Country Link
US (1) US20100249209A1 (de)
EP (2) EP2034017B1 (de)
JP (1) JP5312024B2 (de)
KR (4) KR20090031557A (de)
CN (2) CN101495630B (de)
AT (1) ATE542897T1 (de)
AU (1) AU2007255677B2 (de)
CA (2) CA2654978C (de)
RU (1) RU2449016C2 (de)
WO (1) WO2007142336A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357018B (es) * 2013-12-18 2018-06-05 Instituto Nac De Medicina Genomica Método de diagnóstico temprano de carcinoma hepatocelular.
CN116555325A (zh) * 2023-04-11 2023-08-08 内蒙古农业大学 本氏烟m6A甲基化酶基因在抗病毒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2155066C2 (ru) * 1993-03-31 2000-08-27 Про-Ньюрон, Инк. Ингибитор пролиферации стволовых клеток и его использование
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5776679A (en) * 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
DE19928862A1 (de) * 1999-06-24 2001-01-04 Keiper Gmbh & Co Befestigungsvorrichtung für einen Kindersitz
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
AU2003223661A1 (en) * 2002-04-15 2003-11-03 Rigel Pharmaceuticals, Inc. Methods of assaying for cell cycle modulators
US20030232436A1 (en) * 2002-06-14 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of E2-EPF expression
AU2003275065A1 (en) * 2002-09-20 2004-04-08 Wayne State University Molecular targets of cancer and aging
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US8065093B2 (en) * 2004-10-06 2011-11-22 Agency For Science, Technology, And Research Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
CA2580883A1 (en) * 2004-10-14 2006-04-27 Novartis Ag E2-epf5, a novel therapeutic protein and target

Also Published As

Publication number Publication date
AU2007255677A2 (en) 2009-02-12
WO2007142336A1 (ja) 2007-12-13
US20100249209A1 (en) 2010-09-30
EP2034017A1 (de) 2009-03-11
RU2008152780A (ru) 2010-07-20
CN101495630A (zh) 2009-07-29
RU2449016C2 (ru) 2012-04-27
CA2654978C (en) 2016-05-10
EP2412805A1 (de) 2012-02-01
CN101495630B (zh) 2012-12-26
KR20120030608A (ko) 2012-03-28
EP2034017B1 (de) 2012-01-25
CA2654978A1 (en) 2007-12-13
CA2771971A1 (en) 2007-12-13
AU2007255677A1 (en) 2007-12-13
CN102618545B (zh) 2014-12-10
EP2412805B1 (de) 2014-04-30
EP2034017A4 (de) 2010-08-04
KR20090031557A (ko) 2009-03-26
JPWO2007142336A1 (ja) 2009-10-29
AU2007255677B2 (en) 2013-01-24
KR20140024054A (ko) 2014-02-27
KR101496745B1 (ko) 2015-03-04
JP5312024B2 (ja) 2013-10-09
KR20110013578A (ko) 2011-02-09
CN102618545A (zh) 2012-08-01

Similar Documents

Publication Publication Date Title
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
CY1109892T1 (el) Φυτα ανθεκτικα στην πιεση
ATE479740T1 (de) Zusammensetzungen für bakteriell vermitteltes gen-silencing sowie verfahren zur verwendung davon
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
DE602004017426D1 (de) Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
PH12018000128A1 (en) Pesticidal gene and use thereof
ATE450547T1 (de) Eml4-alk-fusionsgen
EA201171131A1 (ru) Усовершенствованное определение экспрессии генов
ATE515488T1 (de) Click-chemie zur herstellung von reportermolekülen
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
CY1124197T1 (el) Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
CR11504A (es) Deteccion mejorada de la expresion de mage-a
ATE411400T1 (de) Verfahren zur verwendung von riboprimern zur strangverdrängungsreplikation von zielsequenzen
MX2007009809A (es) Amplificacion de sonda por seleccion.
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
MX2018014163A (es) Composiciones de nucleotido marcados y metodos para el secuenciamiento de acido nucleico.
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
ATE522608T1 (de) Primer und sonde zum nachweis von mycobacterium avium sowie verfahren zum nachweis von mycobacterium avium unter verwendung des primers bzw. der sonde
ATE542897T1 (de) An der immortalisierung einer menschlichen krebszelle beteiligtes gen und verwendung davon
EP1767653A4 (de) Sonde zur diagnose von marfans-syndrom sowie verfahren zum screening mit der sonde
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
ATE529521T1 (de) Pflanzliche eizellentranskriptionskontrollsequenzen
DE602004032114D1 (de) Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
ATE441728T1 (de) Mit cmv-resistenz assoziierter molekularer marker und verwendung davon